Merger Announced
Fulcrum Therapeutics and Slate Medicines merger
Announced 17 Aug 2026
Advisers
Other advisers
- Legal adviser
- Target
- Slate Medicines
- Acquirer
- Fulcrum Therapeutics
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Leyden Labs acquisition of RIGImmune Sep 2026 · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Novo Nordisk stake in Orbis Medicines Sep 2026 · Biotech
- Eli Lilly and Company acquisition of Merida Biosciences Aug 2026 · US$2.9bn · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
Sources
- 17 Aug 2026 Press release (EX-99.1, exhibit), Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to sec.gov
- 17 Aug 2026 Goodwin Advises Fulcrum Therapeutics on Merger with Slate Medicines and $245 Million Private Placement Financing goodwinlaw.com
- 18 Aug 2026 Slate Medicines to Merge With Fulcrum Therapeutics cooley.com
